Jiasheng Wang

Summary Aplastic anaemia (AA) is a rare immune‐related adverse events (irAEs) after immune checkpoint inhibitors (ICIs) administration with poorly understood incidence and outcomes. We analysed an electronic health record database of 52 303 ICI‐treated patients and found 77 (0.15%) cases of AA, with a median onset of 126 days (interquartile range, 58–363 days). The most used treatment for AA was systemic glucocorticoids 60 (77.9%) and 32 (41.6%) patients were able to resume ICI within 1 year. Patients diagnosed with AA had a steep decline in overall survival (OS) within the first 120 days; when compared to propensity score‐matched patients without AA, they had a significantly worse OS (hazard ratio 1.72, 95% confidence interval 1.19–2.50; p = 0.003).